Neurotoxicity of the pyrimidine synthesis inhibitor N-phosphonoacetyl-L-aspartate

R. G. Wiley, Richard J. Gralla, E. S. Casper, N. Kemeny

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

PALA (N-phosphonoacetyl-L-aspartate) impairs de novo pyrimidine biosynthesis by inhibiting the enzyme aspartate transcarbamylase. During cancer chemotherapy trials the drug was given by weekly intravenous infusion. Seizures developed in 9 (11%) of the first 80 patients to receive a total dose of 9 gm/m2 or more. Seven of the affected patients had structural brain lesions; they developed seizures at a lower total dose (median of 16.4 gm/m2) than the 2 patients without clinically detectable brain lesions (115 to 130 gm/m2). Reversible encephalopathy was observed in 6 (7.5%) additional patients without clinically detectable cause other than PALA. Both seizures and encephalopathy began after the second dose of PALA or later. Experiments in rats demonstrated similar delay-onset seizures after two or three combined systemic and intracerebral doses of PALA at 4-day intervals. Concurrent administration of uridine or carbamyl aspartate prevented the development of seizures in rats, indicating that pyrimidine starvation of the central nervous system was responsible for PALA neurotoxicity.

Original languageEnglish (US)
Pages (from-to)175-183
Number of pages9
JournalAnnals of Neurology
Volume12
Issue number2
StatePublished - 1982
Externally publishedYes

Fingerprint

NSC 224131
Seizures
Brain Diseases
Aspartate Carbamoyltransferase
Uridine
Brain
Starvation
Intravenous Infusions
Aspartic Acid
Central Nervous System
pyrimidine
Drug Therapy

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Neurotoxicity of the pyrimidine synthesis inhibitor N-phosphonoacetyl-L-aspartate. / Wiley, R. G.; Gralla, Richard J.; Casper, E. S.; Kemeny, N.

In: Annals of Neurology, Vol. 12, No. 2, 1982, p. 175-183.

Research output: Contribution to journalArticle

Wiley, R. G. ; Gralla, Richard J. ; Casper, E. S. ; Kemeny, N. / Neurotoxicity of the pyrimidine synthesis inhibitor N-phosphonoacetyl-L-aspartate. In: Annals of Neurology. 1982 ; Vol. 12, No. 2. pp. 175-183.
@article{b4cef21a70f248f3ac8782b9475755c1,
title = "Neurotoxicity of the pyrimidine synthesis inhibitor N-phosphonoacetyl-L-aspartate",
abstract = "PALA (N-phosphonoacetyl-L-aspartate) impairs de novo pyrimidine biosynthesis by inhibiting the enzyme aspartate transcarbamylase. During cancer chemotherapy trials the drug was given by weekly intravenous infusion. Seizures developed in 9 (11{\%}) of the first 80 patients to receive a total dose of 9 gm/m2 or more. Seven of the affected patients had structural brain lesions; they developed seizures at a lower total dose (median of 16.4 gm/m2) than the 2 patients without clinically detectable brain lesions (115 to 130 gm/m2). Reversible encephalopathy was observed in 6 (7.5{\%}) additional patients without clinically detectable cause other than PALA. Both seizures and encephalopathy began after the second dose of PALA or later. Experiments in rats demonstrated similar delay-onset seizures after two or three combined systemic and intracerebral doses of PALA at 4-day intervals. Concurrent administration of uridine or carbamyl aspartate prevented the development of seizures in rats, indicating that pyrimidine starvation of the central nervous system was responsible for PALA neurotoxicity.",
author = "Wiley, {R. G.} and Gralla, {Richard J.} and Casper, {E. S.} and N. Kemeny",
year = "1982",
language = "English (US)",
volume = "12",
pages = "175--183",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Neurotoxicity of the pyrimidine synthesis inhibitor N-phosphonoacetyl-L-aspartate

AU - Wiley, R. G.

AU - Gralla, Richard J.

AU - Casper, E. S.

AU - Kemeny, N.

PY - 1982

Y1 - 1982

N2 - PALA (N-phosphonoacetyl-L-aspartate) impairs de novo pyrimidine biosynthesis by inhibiting the enzyme aspartate transcarbamylase. During cancer chemotherapy trials the drug was given by weekly intravenous infusion. Seizures developed in 9 (11%) of the first 80 patients to receive a total dose of 9 gm/m2 or more. Seven of the affected patients had structural brain lesions; they developed seizures at a lower total dose (median of 16.4 gm/m2) than the 2 patients without clinically detectable brain lesions (115 to 130 gm/m2). Reversible encephalopathy was observed in 6 (7.5%) additional patients without clinically detectable cause other than PALA. Both seizures and encephalopathy began after the second dose of PALA or later. Experiments in rats demonstrated similar delay-onset seizures after two or three combined systemic and intracerebral doses of PALA at 4-day intervals. Concurrent administration of uridine or carbamyl aspartate prevented the development of seizures in rats, indicating that pyrimidine starvation of the central nervous system was responsible for PALA neurotoxicity.

AB - PALA (N-phosphonoacetyl-L-aspartate) impairs de novo pyrimidine biosynthesis by inhibiting the enzyme aspartate transcarbamylase. During cancer chemotherapy trials the drug was given by weekly intravenous infusion. Seizures developed in 9 (11%) of the first 80 patients to receive a total dose of 9 gm/m2 or more. Seven of the affected patients had structural brain lesions; they developed seizures at a lower total dose (median of 16.4 gm/m2) than the 2 patients without clinically detectable brain lesions (115 to 130 gm/m2). Reversible encephalopathy was observed in 6 (7.5%) additional patients without clinically detectable cause other than PALA. Both seizures and encephalopathy began after the second dose of PALA or later. Experiments in rats demonstrated similar delay-onset seizures after two or three combined systemic and intracerebral doses of PALA at 4-day intervals. Concurrent administration of uridine or carbamyl aspartate prevented the development of seizures in rats, indicating that pyrimidine starvation of the central nervous system was responsible for PALA neurotoxicity.

UR - http://www.scopus.com/inward/record.url?scp=0020066372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020066372&partnerID=8YFLogxK

M3 - Article

C2 - 7125606

AN - SCOPUS:0020066372

VL - 12

SP - 175

EP - 183

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 2

ER -